2022Chinese Journal of DermatologyRequires access

Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application

You Ruixuan, Zhuotong Zeng, Xiangning Qiu, Rong Xiao

Open publisher page 1 citations

Abstract

摘要: 【摘要】 白细胞介素17(IL-17)已被证明与各种炎症性皮肤病的发病密切相关,其主要来源是IL-23辅助分化的Th17细胞,因此IL-23/Th17轴是治疗炎症性皮肤病的新兴靶点。最新的临床试验表明,IL-17、IL-23和IL-12/23拮抗剂在治疗银屑病、特应性皮炎、化脓性汗腺炎、毛发红糠疹和SAPHO综合征患者中显示出良好的疗效与安全性。本文综述IL-23/Th17轴在炎症性皮肤病发生中的分子信号通路和病理生理基础的研究进展以及相应生物制剂的临床应用。

About this research paper

What this paper is about

摘要: 【摘要】 白细胞介素17(IL-17)已被证明与各种炎症性皮肤病的发病密切相关,其主要来源是IL-23辅助分化的Th17细胞,因此IL-23/Th17轴是治疗炎症性皮肤病的新兴靶点。最新的临床试验表明,IL-17、IL-23和IL-12/23拮抗剂在治疗银屑病、特应性皮炎、化脓性汗腺炎、毛发红糠疹和SAPHO综合征患者中显示出良好的疗效与安全性。本文综述IL-23/Th17轴在炎症性皮肤病发生中的分子信号通路和病理生理基础的研究进展以及相应生物制剂的临床应用。

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

摘要: 【摘要】 白细胞介素17(IL-17)已被证明与各种炎症性皮肤病的发病密切相关,其主要来源是IL-23辅助分化的Th17细胞,因此IL-23/Th17轴是治疗炎症性皮肤病的新兴靶点。最新的临床试验表明,IL-17、IL-23和IL-12/23拮抗剂在治疗银屑病、特应性皮炎、化脓性汗腺炎、毛发红糠疹和SAPHO综合征患者中显示出良好的疗效与安全性。本文综述IL-23/Th17轴在炎症性皮肤病发生中的分子信号通路和病理生理基础的研究进展以及相应生物制剂的临床应用。

Key concepts: Interleukin 23, Interleukin 17, Interleukin, Medicine, Immunology, Interleukin 1β, Inflammation, Cytokine

Related papers

Back to paper searchBrowse research topicsOriginal source
Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application — Research Paper | ScholarLens